Association of Reproductive Health Professionals
Association of Reproductive Health Professionals
Reproductive Health Topics Publications & Resources Professional Education Newsroom Membership Policy & Advocacy About Us
Testimony & Letters
Send To A Friend Send To A Friend Bookmark this Page Share this page
Testimony & Letters

In order to encourage policy formation and decision-making based on sound science at the federal level, ARHP often provides expert testimony in front of federal government decision making bodies and committees. ARHP has provided testimony on various reproductive health care topics including emergency contraception, the safety and efficacy of oral contraceptives, approvals of new medical devices, and issues related to the effects of environmental toxins on reproductive health in front of various agencies and committees within the US Department of Health and Human Services (HHS).

ARHP Letter to the American Board of Obstetricians and Gynecologists
November 2013

Statement on MarginProbe to the FDA General and Plastic Surgery Devices Panel Advisory Committee
June 21, 2012

Statement from the Association of Reproductive Health Professionals to the President’s Council of Advisors on Science and Technology
Presented in response to Secretary Sebelius’ decision to overrule the FDA’s recommendation to make Plan B One-Step over the counter
January 6, 2012

Statement to the Office of Research on Women’s Health, the National Institute of Health and the Department of Health and Human Services
This is the group convened through the Institute of Medicine and charged with recommending which preventive services are necessary for women’s health and well-being and should be considered in the development of comprehensive guidelines for preventive services for women. Making sure that the full range of reproductive health care is included on this list is critical because these are the screenings and services that will be covered without cost-sharing in the new health plans from the Affordable Care Act. This is a prime opportunity to codify the essential nature of family planning and reproductive health services into the implementation of health care reform.
March 9, 2011 

Testimony Presented to the United States Food and Drug Administration’s Advisory Committee for Reproductive Health Drugs
Food and Drug Administration’s Advisory Committee for Reproductive Health Drugs
June 17, 2010

Statement to the Office of Research on Women’s Health, the National Institute of Health and the Department of Health and Human Services
ORWH/NIH/DHHS, and the Northwestern University, Feinberg School of Medicine, and Northwestern Memorial Hospital co-hosted the fourth in a series of four public hearings and scientific workshops to update the Women's Health Research Agenda at the NIH for the coming decade.
October 14, 2009  

Statement to the Office of Research on Women’s Health, the National Institute of Health and the Department of Health and Human Services
ORWH/NIH/DHHS and the Warren Alpert Medical School of Brown University and Women & Infants Hospital of Rhode Island co-hosted the third in a series of four public hearings and scientific workshops to update the Women's Health Research Agenda at the NIH for the coming decade.
September 21, 2009

Statement to the Science Board to the Food and Drug Administration (FDA)
Submitted in response to FDA meeting to discuss updates regarding the continued assessment of BPA in FDA-regulated products
August 18, 2009

Statement in Support of Warnings Regarding Bisphenol A’s Possible Adverse Effects on Human Reproductive Health and Carcinogenicity
Presented to the Developmental and Reproductive Toxicant Identification Committee of California EPA OEHHA’s Science Advisory Board, Oakland, California
July 15, 2009

Submission to the Committee on Preventive Services for Women
The Office of Research on Women’s Health/NIH/DHHS, the UCSF Department of Obstetrics, Gynecology, and Reproductive Sciences and the UCSF National Center of Excellence in Women's Health co-hosted the second in a series of four public hearings and scientific workshops to update the Women’s Health Research Agenda at the NIH for the coming decade.
May, 28, 2009

Testimony Regarding Premarket Approval Application for the Female Condom
Food and Drug Administration, Obstetrics and Gynecology Devices Panel
of the Medical Devices Advisory Committee
December 11, 2008

Statement to the Bisphenol A (BPA) Subcommittee of the Science Board to the Food and Drug Administration
Submitted in response to FDA meeting to discuss the draft assessment of BPA for use in food containers; Request for Public Comment FDA-2008-N-0038
September 16, 2008

Presentation to the ICCR Preparatory Meeting on toxic substances in personal care products and cosmetics;
Request for health care providers to be present during ICCR meetings
June 19, 2008

Testimony Regarding Adiana Transcervical Sterilization System
Food and Drug Administration Obstetrics and Gynecology Devices, Panel of the Medical Devices Advisory Committee
December 13, 2007

Statement in Support of Warnings Regarding Bisphenol A’s Possible Adverse Effects on Human Reproductive Health and Carcinogenicity
Presented to the National Toxicology Program’s Center for the Evaluation of Risks To Human Reproduction’s Second Bisphenol A Expert Panel Meeting
August 6, 2007

Measuring hormonal contraceptive efficacy
Testimony Presented to the United States Food and Drug Administration’s Advisory Committee for Reproductive Health Drugs
January 24, 2007

Statement in Support of the Approval of the HPV Vaccine
Presented to the United States Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee
May 18, 2006